Spruce Biosciences

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

SPRB

Biotech

News

Health Care

Movers

Trading Ideas

General

Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows dose-dependent trends.

Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder

Contracts

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

pharma lab worker ai

Analyst Color

Price Target

Analyst Ratings

Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compliance. Analysts downgrade ratings and adjust price targets amid uncertainty.

Spruce Biosciences&#39; Hormone Treatment Stumbles In Trials, Prompts Stock Freefall

Spruce Biosciences Inc

SPAREBANKEN 1 OSTLANDET by Sparebank 1 Ostlandet

Press Releases

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Recognized as a Bay Area Best Place to Work

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

ABVC BioPharma

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Imunon

Kairos Pharma

Leap Therapeutics

MEI Pharma

Marker Therapeutics

MetaVia

Ocean Biomedical

PharmaCyte Biotech

SAB Biotherapeutics

Senti Biosciences

Synlogic

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

JMP Securities

RBC Capital

Leerink Partners

SVB Leerink

Credit Suisse

Comments

Spruce Biosciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga